UNITED GUARDIAN INC. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for United-Guardian, Inc. for the period ended June 30, 2026. The company operates as a single segment, manufacturing specialty cosmetic, personal care, sexual wellness ingredients, and healthcare products (pharmaceuticals and medical lubricants) through its Guardian Laboratories division. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Net Sales | $3,108,267 | $2,838,225 | $5,980,489 | $5,319,352 |
| Gross Profit | $1,545,802 | $1,497,371 | $2,970,235 | $2,855,422 |
| Gross Margin | 49.7% | 52.8% | 49.7% | 53.7% |
| Net Income | $728,579 | $626,826 | $1,547,481 | $1,187,721 |
| Diluted EPS | $0.16 | $0.14 | $0.34 | $0.26 |
| Operating Cash Flow (YTD) | $2,124,531 (vs. $625,323 YTD 2025) | |||
| Cash & Equivalents | $2,390,738 (as of June 30, 2026) | |||
| Working Capital | $10,977,452 (as of June 30, 2026) | |||
| Debt | None reported |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% in Q2 and 12% YTD compared to 2025. Growth was driven by a 44% increase in cosmetic and sexual wellness ingredients sales (Q2) and an 11% increase in pharmaceutical sales (YTD).
- Margin Compression: Gross margin decreased from 52.8% to 49.7% in Q2. Management attributes this to higher overhead costs per unit due to lower production volumes in 2025.
- Unusual Items: The company recognized $36,360 in settlement income in Q2 2026 (totaling $339,493 YTD) from a contract manufacturer regarding a facility shutdown in 2023-2024. This was a non-recurring benefit.
- Investment Gains: Net gain on marketable securities increased to $48,365 in Q2 2026 from $24,576 in Q2 2025, driven by market value appreciation.
- Dividends: The dividend per share was reduced to $0.25 in 2026 from $0.35 in 2025, resulting in lower cash outflows for financing activities.
Outlook, Risks, and Management Commentary
- Strategic Initiatives: The company entered a new distribution agreement with Brenntag Specialties in January 2026 to expand the sexual wellness segment in North America and France. Sales in this segment are just beginning.
- Pharmaceutical Growth: Renacidin (the primary pharmaceutical product) was added to two major Pharmacy Benefit Manager (PBM) formularies in June and July 2026. Management expects this to drive future demand.
- Risks:
- Customer Concentration: Four distributors (largest cosmetic and three pharmaceutical) accounted for 79% of Q2 sales and 85% of accounts receivable.
- Supplier Concentration: Three suppliers provided 83% of raw materials in the first half of 2026. The company relies on a single contract manufacturer for Renacidin.
- Geopolitical/Trade: Ongoing tensions and U.S. tariff policies may impact freight costs, raw material availability, and customer demand.
- Liquidity: The company maintains a strong current ratio of 7.3 to 1 and believes working capital is sufficient for the next 12 months.
Investor Verification Checklist
- Sustainability of Revenue Growth: Verify if the 44% increase in cosmetic/sexual wellness sales is sustainable or a one-time recovery from distributor overstocking in 2025.
- Renacidin Formulary Impact: Monitor future quarters to confirm if the new PBM formulary inclusions translate to measurable sales growth.
- Margin Trends: Watch for continued pressure on gross margins due to production volume inefficiencies.
- Concentration Risk: Assess the financial health of the top four distributors and the single contract manufacturer, as their failure would materially impact operations.
- Dividend Policy: Note the reduction in dividend payout; verify if this is a temporary measure or a shift in capital allocation strategy.